Artiva Biotherapeutics is a clinical-stage biotechnology company focused on developing and advancing natural killer (NK) cell-based therapies. With a mission to bring effective, safe, and accessible treatments to patients, Artiva is deeply committed to transforming the care of those living with devastating autoimmune diseases and cancers. By harnessing the power of NK cells, the company aims to overcome current limitations in cell therapy and make these innovative treatments broadly available to patients in need.